GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » ROIC %

Algernon Pharmaceuticals (XCNQ:AGN) ROIC % : -54.35% (As of Nov. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Algernon Pharmaceuticals's annualized return on invested capital (ROIC %) for the quarter that ended in Nov. 2023 was -54.35%.

As of today (2024-04-26), Algernon Pharmaceuticals's WACC % is 10.64%. Algernon Pharmaceuticals's ROIC % is -80.44% (calculated using TTM income statement data). Algernon Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Algernon Pharmaceuticals ROIC % Historical Data

The historical data trend for Algernon Pharmaceuticals's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals ROIC % Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
ROIC %
Get a 7-Day Free Trial Premium Member Only -73.80 -155.28 -125.79 -100.17 -114.35

Algernon Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -141.02 -91.52 -81.25 -83.89 -54.35

Competitive Comparison of Algernon Pharmaceuticals's ROIC %

For the Biotechnology subindustry, Algernon Pharmaceuticals's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's ROIC % distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's ROIC % falls into.



Algernon Pharmaceuticals ROIC % Calculation

Algernon Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Aug. 2023 is calculated as:

ROIC % (A: Aug. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Aug. 2022 ) + Invested Capital (A: Aug. 2023 ))/ count )
=-5.242 * ( 1 - 0% )/( (5.314 + 3.854)/ 2 )
=-5.242/4.584
=-114.35 %

where

Algernon Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Nov. 2023 is calculated as:

ROIC % (Q: Nov. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Aug. 2023 ) + Invested Capital (Q: Nov. 2023 ))/ count )
=-2.088 * ( 1 - 0% )/( (3.854 + 3.829)/ 2 )
=-2.088/3.8415
=-54.35 %

where

Note: The Operating Income data used here is four times the quarterly (Nov. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals  (XCNQ:AGN) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Algernon Pharmaceuticals's WACC % is 10.64%. Algernon Pharmaceuticals's ROIC % is -80.44% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Algernon Pharmaceuticals ROIC % Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (XCNQ:AGN) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (XCNQ:AGN) Headlines

No Headlines